Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
Tony W. Ho(Johns Hopkins University), David Michelson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lars Edvinsson(Lund University), Eric Pearlman(University of California, San Francisco), Janelle M. Koppenhaver(Mercer (Czechia)), Ying Zhang(Mercer (Czechia)), Christopher Lines(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter J. Goadsby(King's College London), Kathryn M. Connor(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaoyin Fan(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 263
Related Papers
Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia
|The Journal of Experimental Medicine|1997|532
N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis
|Nature Communications|2020|453
Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP
|Nature Communications|2016|446